DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

SUPPLEMENT APPROVAL

Our STN: BL **125254/565**

Seqirus Pty Ltd.
Attention: Kelly T. Boyle
(Authorized U.S. Agent)
Biologics Consulting Group, Inc.
400 N. Washington Street
Suite 100
Alexandria, VA 22314

Dear Ms. Boyle:

We have approved your request to supplement your biologics license application for Influenza Vaccine (Afluria ®), manufactured at your Marburg, Germany; (b) (4) ; and Parkville, Australia facilities, to include a quadrivalent formulation (Afluria Quadrivalent) for use in persons 18 years of age and older.

The review of this product was associated with the following National Clinical Trial (NCT) number: NCT02214225.

Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels. In addition, please submit three original paper copies for carton and container final printed labeling. All final labeling should be submitted as Product Correspondence to this biologics license application (BLA) at the time of use (prior to marketing) and include implementation information on FDA Form 356h.

In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled, "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these change(s).

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages birth to < 6 months of age because the product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in this age group **and** is not likely to be used in a substantial number of pediatric patients younger than 6 months of age. Available data indicate that serum antibody responses to inactivated influenza vaccines in infants <6 months of age are not as robust as in older children due to inherent immaturity of the immune system and interference from maternal antibody. Therefore, there is no meaningful benefit over initiating vaccination at 6 months of age.

We are deferring submission of your pediatric studies for ages 6 months to 17 years for this application because this product is ready for approval for use in adults and the pediatric studies in children 6 months to 17 years of age have not been completed.

Your deferred pediatric studies required under 505B(a) of the Federal Food, Drug, and Cosmetic Act (FDCA) are required postmarketing studies. The status of these postmarketing studies must be reported according to 21 CFR 601.70 and section 505B(a)(3)(B) of the FDCA. These required studies are listed below:

1. Deferred pediatric study under PREA, to evaluate the immunogenicity and safety of Afluria Quadrivalent in the pediatric population 5 through 17 years of age

   Final Protocol Submission: July 31, 2015 (completed)

   Study Completion Date: June 30, 2016 (completed)

   Final Report Submission: December 31, 2016

2. Deferred pediatric study under PREA, to evaluate the immunogenicity and safety of Afluria Quadrivalent in the pediatric population 6 months through 4 years of age

   Final Protocol Submission: July 31, 2016 (completed)

   Study Completion Date: June 30, 2017

   Final Report Submission: December 31, 2017

Submit final study reports to this BLA. For administrative purposes, all submissions related to these required pediatric postmarketing studies must be clearly designated **"Required Pediatric Assessment(s)."**

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We acknowledge your written commitments as described in your letter of July 6, 2016, as outlined below:

3. To establish a pregnancy registry to prospectively collect data on reported exposures to Afluria Quadrivalent during pregnancy and evaluate pregnancy outcomes. The registry will enroll a minimum of 500 evaluable subjects.

   Final Protocol Submission: September 30, 2017

   Study/Trial Completion Date: August 31, 2020

   Final Report Submission: February 28, 2021

Please submit clinical protocols to your IND15974, with a cross-reference letter to this BLA, STN BL 125254 explaining that the protocols were submitted to the IND.

If the information in the final study report supports a change in the labeling, the final study report should be submitted as a supplement. Supplements in support of labeling changes based on a postmarketing study report may be subject to a user fee. Please use the following designators to label prominently all submissions, including supplements, relating to these postmarketing study commitments as appropriate:

- **Postmarketing Commitment – Correspondence**
- **Postmarketing Commitment – Final Study Report**
- **Supplement contains Postmarketing Commitments – Final Study Report**

For each postmarketing study subject to the reporting requirements of 21 CFR 601.70, you must describe the status in an annual report on postmarketing studies for this product. Label your annual report an Annual Status Report of Postmarketing Requirements/Commitments and submit it to the FDA each year within 60 calendar days of the anniversary date of this letter until all Requirements and Commitments subject to the reorting requirements of section 506B of the FDCA are fulfilled or released. The status report for each study should include:

- The sequential number for each study as shown in this letter,
- information to identify and describe the postmarketing commitment,
- the original schedule for the commitment,
- the status of the commitment (i.e., pending, ongoing, delayed, terminated, or submitted), and
- an explanation of the status including, for clinical studies, the patient accrual rate (i.e., number enrolled to date and the total planned enrollment).

As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our Web site (http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm).

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

Wellington Sun, M.D.
Director
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment: Approved Final Draft Labeling